v3.22.2.2
SEGMENT REPORTING
 9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Segment Reporting [Abstract]    
SEGMENT REPORTING

NOTE 10 – SEGMENT REPORTING

 

Operating segments are defined as the components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision makers in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision makers direct the allocation of resources to operating segments based on the profitability, cash flows, and growth opportunities of each respective segment.

 

The Company classifies its business interests into reportable segments which are:

 

●Trxade– Inc. - Web based pharmaceutical marketplace platform – B2B sales
●CSP - Community Specialty Pharmacy, LLC – Licensed retail pharmacy – B2C sales
●I–tegra - Integra Pharm–, LLC - Licensed wholesaler of brand, generic and non-drug products – B2B sales
●Unall–cated - Other – corporate overhead expense, Alliance Pharma Solutions, LLC and Bonum Health, LLC

Nine Months Ended September 30, 2022  Trxade, Inc.   CSP   Integra   Unallocated   Total 
Revenue  $4,001,670   $905,083   $3,949,772   $62,787   $8,919,312 
Gross Profit   4,001,670    (114,387)   (41,462)   62,787    3,908,608 
Segment Assets   1,853,474    236,827    454,783    2,111,177    4,689,261 
Segment Profit (Loss )   1,320,138    (363,212)   (493,203)   (3,070,562)   (2,606,839)
Cost of Sales  $-   $1,019,470  $3,991,234  $-   $5,010,704

 

Nine Months Ended September 30, 2021  Trxade, Inc.   CSP   Integra   Unallocated   Total 
Revenue  $3,653,269   $1,287,296   $2,511,270   $49,700   $7,501,535 
Gross Profit   3,652,015    123,470    (319,104)   49,362    3,505,743 
Segment Assets   1,487,657    (404,174)   563,396    3,867,221    5,514,101 
Segment Profit (Loss)   1,511,809    (89,025)   (2,500,032)   (3,454,295)   (4,531,543)
Cost of Sales  $1,254   $1,163,826   $2,830,374   $338   $3,995,792 

 

NOTE 11 – SEGMENT REPORTING

 

The Company classifies its business interests into reportable segments which are Trxade, Inc., Community Specialty Pharmacy, LLC, Integra Pharma, LLC and Other (Unallocated). Operating segments are defined as the components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision makers in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision makers direct the allocation of resources to operating segments based on the profitability, cash flows, and growth opportunities of each respective segment.

 

Year Ended

December 31, 2021

  Trxade, Inc.  

Community

Specialty

Pharmacy, LLC

  

Integra

Pharma, LLC

   Unallocated   Total 
Revenue  $4,924,015   $1,652,841   $3,250,561   $62,016   $9,889,433 
Gross Profit  $4,921,084   $156,785   $(393,582)  $61,678   $4,745,965 
Segment Assets  $2,273,330   $(431,593)  $565,619   $3,358,808   $5,766,164 
Segment Profit/Loss  $1,977,938   $(128,563)  $(2,749,028)  $(4,416,230)  $(5,315,883)

 

Year Ended

December 31, 2020

  Trxade, Inc.  

Community

Specialty

Pharmacy, LLC

  

Integra

Pharma, LLC

   Unallocated   Total 
Revenue  $5,546,746   $1,653,924   $9,877,067   $44,783   $17,122,520 
Gross Profit  $5,546,746    107,771    8,374   $44,431   $5,707,322 
Segment Assets  $2,076,934   $(457,784)   2,698,357   $5,475,195   $9,792,702 
Segment Profit/Loss  $3,309,128   $(900,427)  $(531,092)  $(4,413,660)  $(2,536,051)